Key Points
ROG.SW gained 0.5% to CHF322.3 with 778,976 shares traded
P/E of 20.1 and 3.04% dividend yield offer attractive valuations
Technical oversold signals (RSI 35.92) suggest potential bounce opportunity
Meyka AI rates ROG.SW B+ with strong free cash flow growth of 31.8%
Roche Holding AG’s participation shares, trading as ROG.SW on the SIX exchange, gained 0.5% today, closing at CHF322.3 with strong intraday activity. The Swiss pharmaceutical giant saw 778,976 shares trade hands, reflecting investor interest in the healthcare sector’s largest player. With a market cap of CHF256.6 billion, Roche remains a cornerstone holding for many portfolios. The stock trades near its 50-day average of CHF350.14, suggesting recent consolidation. Today’s modest gain reflects steady demand for the company’s diversified pharmaceutical and diagnostics portfolio.
ROG.SW Stock Performance and Market Activity
ROG.SW opened at CHF322.0 and reached a high of CHF323.5 during today’s session, with a low of CHF317.4. The 0.49% gain added CHF1.60 to yesterday’s close of CHF320.7. Trading volume of 778,976 shares represents about 68% of the 30-day average, indicating moderate but meaningful participation.
The stock remains below its 50-day moving average of CHF350.14, down 7.9% from that level. However, it trades well above the 200-day average of CHF295.75, confirming an intermediate uptrend. Year-to-date, ROG.SW is down just 0.98%, showing resilience despite broader healthcare sector headwinds of -3.18% this year.
Valuation and Financial Metrics for ROG.SW Analysis
ROG.SW trades at a P/E ratio of 20.1, slightly above the healthcare sector average of 30.41, suggesting reasonable valuation for a quality compounder. The stock’s price-to-sales ratio of 4.17 reflects premium pricing typical of large-cap pharma leaders. Earnings per share stand at CHF16.03, with a dividend yield of 3.04% and annual dividend of CHF9.80 per share.
Key profitability metrics show strong fundamentals: net profit margin of 20.9%, return on equity of 41.2%, and return on assets of 12.8%. Free cash flow per share reaches CHF14.91, supporting the dividend and buyback programs. Track ROG.SW on Meyka for real-time updates on these metrics and technical signals.
Market Sentiment and Technical Indicators for ROG.SW Stock
The technical picture shows mixed signals. The RSI at 35.92 indicates oversold conditions, suggesting potential for a bounce. However, the MACD at -12.16 with a negative histogram of -3.31 reflects bearish momentum. The ADX at 36.28 confirms a strong downtrend is in place, warning traders to exercise caution.
Volatility remains elevated with the ATR at 10.27. Bollinger Bands show the stock trading near the middle band (CHF340.96), between upper (CHF385.91) and lower (CHF296.01) levels. The Stochastic %K at 30.78 and Williams %R at -64.16 both suggest oversold territory, potentially attracting value buyers looking for entry points.
Growth Outlook and Meyka AI Grade for ROG.SW
Meyka AI rates ROG.SW with a grade of B+, suggesting a neutral stance with selective opportunities. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating reflects balanced risk-reward dynamics in the current market environment.
Recent financial growth shows mixed results: revenue grew 3.2% year-over-year, but net income declined 28% due to one-time charges. However, free cash flow surged 31.8%, demonstrating strong operational cash generation. Operating cash flow grew 24.8%, supporting the company’s ability to fund R&D and shareholder returns. These grades are not guaranteed and we are not financial advisors.
Final Thoughts
ROG.SW stock delivered a modest 0.5% gain today, reflecting steady demand for Roche Holding AG’s healthcare portfolio. The stock trades at reasonable valuations with a P/E of 20.1 and attractive 3.04% dividend yield, appealing to income-focused investors. Technical indicators show oversold conditions, potentially signaling a near-term bounce, though the broader downtrend remains intact. With strong free cash flow generation and a diversified pharmaceutical and diagnostics business, Roche maintains its position as a defensive healthcare holding. Investors should monitor the stock’s ability to reclaim the CHF350 level for confirmation of sustained upside momentum.
FAQs
ROG.SW closed at CHF322.3 on April 24, 2026, up CHF1.60 or 0.5% from the previous close of CHF320.7. The stock traded between CHF317.4 and CHF323.5 during the session with 778,976 shares exchanged.
ROG.SW offers a dividend yield of 3.04% with an annual dividend of CHF9.80 per share. The payout ratio stands at 35.1%, indicating sustainable dividend coverage from earnings and leaving room for reinvestment.
ROG.SW trades at a P/E ratio of 20.1, below the healthcare sector average of 30.41, suggesting attractive relative valuation. The price-to-sales ratio of 4.17 reflects premium positioning typical of large-cap pharmaceutical leaders.
The RSI at 35.92 and Stochastic %K at 30.78 indicate oversold conditions, potentially attracting buyers. However, the ADX at 36.28 confirms a strong downtrend, and the MACD remains negative, suggesting caution before committing capital.
Meyka AI rates ROG.SW with a B+ grade, suggesting a neutral recommendation. This grade incorporates benchmark comparisons, sector performance, financial metrics, and analyst consensus to provide a balanced assessment of risk and opportunity.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)